Request Info


Ask for our annual reports or more information
Email Us

Email Alerts

Sign up for email alerts
Email Alerts
Investor Relations

News Releases

RSS RSS Feeds
News Release Search
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998
DateTitle  
11/14/2013PCR from Whole Blood, Simplified
CINCINNATI--(BUSINESS WIRE)--Nov. 14, 2013-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the MyTaqTM Blood-PCR Kit, developed for fast, highly-specific PCR direct from whole blood samples. Based on the proven MyTaqTM HS DNA polymerase, in combination with a novel, red-colored, buffer system; the new Bioline MyTaqTM Blood-PCR Kit overcomes the ... 
 Printer Friendly Version
11/7/2013Meridian Bioscience Reports Record Fourth Quarter and Full-Year Operating Results, Declares Regular Cash Dividend, Announces Increased Regular Cash Dividend Rate for Fiscal 2014, and Reaffirms Fiscal 2014 Guidance
CINCINNATI--(BUSINESS WIRE)--Nov. 7, 2013-- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported record fourth quarter and full-year fiscal 2013 net sales of $49.0 million and $188.7 million, respectively, increases of 13% and 9%, respectively, from the same periods of the prior fiscal year; reported record f... 
 Printer Friendly Version
10/31/2013Meridian Life Science Awarded SBIR by Centers for Disease Control and Prevention to Develop Rotavirus Vaccine
MEMPHIS, Tenn.--(BUSINESS WIRE)--Oct. 31, 2013-- Meridian Life Science, Inc., (MLS) of Memphis, Tennessee, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), has been selected by the Centers for Disease Control and Prevention (CDC) to develop a process for manufacture of a rotavirus vaccine. Funding for this activity will be provided through a Small Business Innovation Research (SBIR) contract. Process development will focus on optimiz... 
 Printer Friendly Version
9/9/2013Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2014 and Reaffirms Fiscal 2013 Guidance
CINCINNATI--(BUSINESS WIRE)--Sep. 9, 2013-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today provided the financial community with guidance regarding the Company’s fiscal 2014 sales and earnings estimates. Based on the Company’s business planning and budgeting activities for the fiscal year ending September 30, 2014, management expects net sales to be in the range of $203 to $208 million and per share diluted earnings to be between $0.98 ... 
 Printer Friendly Version
7/25/2013Meridian Bioscience Reports Third Quarter and Nine Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2013 Guidance
CINCINNATI--(BUSINESS WIRE)--Jul. 25, 2013-- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported fiscal 2013 third quarter and nine months net sales of $47.1 million and $139.7 million, respectively, increases of 12% and 8%, respectively, from the same periods of the prior fiscal year; reported third quarter o... 
 Printer Friendly Version
7/2/2013Bioline Launches the MyTaq™ Extract-PCR Kit, Single Tube Extraction of PCR-Ready DNA from Mammalian Tissues
CINCINNATI--(BUSINESS WIRE)--Jul. 2, 2013-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the MyTaqTM Extract-PCR Kit. Powered by the high performance MyTaqTM DNA Polymerase, the MyTaqTM Extract-PCR Kit offers a quick and easy alternative for the extraction and amplification of DNA from a variety of mammalian tissue types. Researchers using the ... 
 Printer Friendly Version
6/10/2013Meridian Bioscience Receives FDA Clearance for New Molecular Amplification Test: illumigene® Mycoplasma
CINCINNATI--(BUSINESS WIRE)--Jun. 10, 2013-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has received FDA clearance for a new molecular diagnostic test for Mycoplasma pneumonia (M. pneumoniae), its fourth assay on the illumigene platform. This innovative test that aids in identifying an important respiratory pathogen is a strong addition to the illumigene platform. Often referred to as “walking pneumo... 
 Printer Friendly Version
4/25/2013Meridian Bioscience Reports Second Quarter and Six Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2013 Guidance
CINCINNATI--(BUSINESS WIRE)--Apr. 25, 2013-- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported fiscal 2013 second quarter and six months net sales of $47.3 million and $92.6 million, respectively, flat and an increase of 6%, respectively, from the same periods of the prior fiscal year; reported second quar... 
 Printer Friendly Version
3/28/2013Meridian Bioscience Recognized by Forbes as One of America’s 100 Most Trustworthy Companies
CINCINNATI--(BUSINESS WIRE)--Mar. 28, 2013-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has been recognized by Forbes as one of America’s 100 Most Trustworthy Companies. The list is selected following a comprehensive evaluation of governance and accounting practices of candidate companies having market capitalization over $250 million. The rankings are based on data from GMI Ratings (GMI) that looks at over 60 governance and account... 
 Printer Friendly Version
3/18/2013Meridian Bioscience Announces illumigene® Group A Streptococcus and illumigene® Group B Streptococcus Tests Categorized “Moderate Complexity” by FDA
CINCINNATI--(BUSINESS WIRE)--Mar. 18, 2013-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced the U.S. Food & Drug Administration (FDA) has re-categorized Meridian’s illumigene® Group A Streptococcus and illumigene® Group B Streptococcus tests as “Moderate Complexity” under the Clinical Laboratory Improvement Amendments (CLIA). Moderately complex tests are assays that are considered to be simple and easy to use. ... 
 Printer Friendly Version
2/6/2013Bioline Launches ISOLATE II, a Precious Find for DNA and RNA Isolation
CINCINNATI--(BUSINESS WIRE)--Feb. 6, 2013-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the high performance ISOLATE II range of nucleic acid purification kits. Based on filter membrane spin column technology with simple bind-wash-elute steps; the new Bioline ISOLATE II kits are designed for fast and efficient isolation of DNA or RNA from ... 
 Printer Friendly Version
1/23/2013Meridian Bioscience Reports First Quarter 2013 Operating Results and Reaffirms Fiscal 2013 Guidance
CINCINNATI--(BUSINESS WIRE)--Jan. 23, 2013-- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported record first quarter net sales of $45.4 million, an increase of 13%, from the same period of the prior fiscal year; reported first quarter operating income of $13.1 million, an increase of 34%, over the same pe... 
 Printer Friendly Version